Novakand Pharma AB (publ) (LARK) — Capital Reinvestment Ratio
Latest as of December 2021:
0.01x
Novakand Pharma AB (publ) (LARK) has a Capital Reinvestment Ratio of 0.01x as of December 2021, meaning it reinvests 0% of its operating cash flow (Skr22.11 Million) in capital expenditures (Skr147.73K). See Novakand Pharma AB (publ) (LARK) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.01x
Capex / Operating Cash Flow
Operating Cash Flow
Skr22.11 Million
SEK
Capital Expenditures
Skr147.73K
SEK
Data as of
Dec 2021
Most recent filing
Novakand Pharma AB (publ) Capital Reinvestment Ratio (2018–2021)
This chart tracks Novakand Pharma AB (publ)'s Capital Reinvestment Ratio across 2 annual periods.
Annual Capital Reinvestment Ratio for Novakand Pharma AB (publ) (2018–2021)
Year-by-year Capital Reinvestment Ratio for Novakand Pharma AB (publ) from 2018 to 2021. For live market cap and broader valuation context, see LARK market cap.
| Year | Reinvestment Ratio | Operating CF (SEK) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2021 | 0.01x | Skr22.11 Million | Skr147.73K | ▼ -99.6% |
| 2018 | 1.89x | Skr227.60K | Skr430.20K | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow